Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors

Citation
Ht. Sorensen et al., Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors, BR J CL PH, 52(3), 2001, pp. 313-318
Citations number
26
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
03065251 → ACNP
Volume
52
Issue
3
Year of publication
2001
Pages
313 - 318
Database
ISI
SICI code
0306-5251(200109)52:3<313:ROSIUO>2.0.ZU;2-V
Abstract
Aims To examine the risk of suicide in users of beta -adrenoceptor blockers , calcium channel blockers, and angiotensin converting enzyme inhibitors. Methods We conducted a cohort study based on linkage of a population-based prescription registry in North Jutland County, Denmark, and the nation, vid e Death Registry. From 1989 to 1995 there were 58 529 users of beta -adreno ceptor blockers, calcium channel blockers, and angiotensin converting enzym e inhibitors. The mortality rates from suicides in the cohort members were compared with the rates in the general population. Results One hundred and four suicides occurred in the cohorts. The standard ized mortality ratio for suicide in users of beta -adrenoceptor blockers wa s 1.6 (95% confidence interval: 1.2-2.1), in users of calcium channel block ers 1.2 (95% confidence interval: 0.8-1.7), and in users of angiotensin con verting enzyme inhibitors 1.2 (95% confidence interval: 0.7-1.8). In users of beta -adrenoceptor blockers, the risk of suicide was increased during th e first 12 months after the start of therapy, standardized mortality ratio 2.1 (95% confidence interval: 1.2-3.5). There was a trend in the standardiz ed mortality ratio of suicide from 0.9 (95% confidence interval: 0.4-1.9) i n users of beta -adrenoceptor blockers with low lipid solubility, to 1.6 (0 .8-2.8) and 2.7 (1.7-4.1) in users of beta -adrenoceptor blockers with medi um and high lipid solubility, respectively. Conclusions Users of medium and high lipid soluble beta -adrenoceptor block ers may have an increased risk of suicide. Users of calcium channel blocker s and angiotensin converting enzyme inhibitors do not seem to have a signif icantly increased risk of suicide.